Between-trial heterogeneity in meta-analyses may be partially explained by reported design characteristics-Reference-Cited by-同舟云学术

Between-trial heterogeneity in meta-analyses may be partially explained by reported design characteristics

Published:2018-03 Issue: Volume:95 Page:45-54
ISSN:0895-4356
Container-title:Journal of Clinical Epidemiology
language:en
Short-container-title:Journal of Clinical Epidemiology

Author:

Rhodes Kirsty M.,Turner Rebecca M.,Savović Jelena,Jones Hayley E.,Mawdsley David,Higgins Julian P.T.

Publisher

Elsevier BV

Subject

Epidemiology

Reference24 articles.

1. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews;Turner;Int J Epidemiol,2012

2. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data;Rhodes;J Clin Epidemiol,2015

3. A re-evaluation of random-effects meta-analysis;Higgins;J R Stat Soc Ser A Stat Soc,2009

4. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials;Schulz;JAMA,1995

5. Association Between Risk-of-Bias Assessments and Results of Randomized Trials in Cochrane Reviews: the ROBES Meta-Epidemiologic Study;Savović;Am J Epidemiol,2017

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. There is a Lack of Clinical Homogeneity in Lower-Limb Tendinopathy Trials: A Scoping Review;Journal of Orthopaedic & Sports Physical Therapy;2024-01

2. A meta-analysis on the effectiveness of functional literacy interventions for adults;Educational Research Review;2023-11

3. Comparative Evaluation of Contrast-Enhanced Spectral Mammography and Digital Breast Tomosynthesis for Diagnosing and Treating Breast Cancer;Medical Science Monitor;2023-10-23

4. Designs used in published therapeutic studies of rare superficial vascular anomalies: a systematic literature search;BMC Medical Research Methodology;2023-08-30

5. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials;BMC Cancer;2023-05-24